In many cardiovascular outcome trials (CVOT) with injectable GLP-1 RAs, the overall effect has been to reduce the rate of important cardiovascular disease outcomes including myocardial infarction, stroke, heart failure hospitalization, or death from cardiovascular disease [4, 5, 7, 27]. The gene discussed is GLP1R; the disease is stroke disorder.